Bailard’s PTC Therapeutics PTCT Stock Holding History

Bailard’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-31,000	Closed	-$1.47M	–	744
2021 Q1	$1.47M	Buy	31,000 +21,000	+210%	+$1.25M	0.05%	229
2020 Q4	$610K	Buy	+10,000	New	+$589K	0.03%	285

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bailard's PTCT Position: Q2 2021 in Review

Bailard sold out of PTC Therapeutics (PTCT) in Q2 2021, closing a stake of 31,000 shares — an estimated $1.47M sold.

Bailard first reported a position in PTCT in Q4 2020 and held it in 2 quarters. The position peaked at $1.47M in Q1 2021. 182 funds tracked by Wall St. Rank hold PTCT as of Q2 2021.

Bailard reported no remaining PTC Therapeutics position as of Q2 2021 after selling out during the quarter.
Bailard sold 31,000 PTC Therapeutics shares in Q2 2021, an estimated $1.47M.
Bailard first reported a position in PTC Therapeutics in Q4 2020 and held it in 2 quarters.
Bailard's PTC Therapeutics position peaked at $1.47M in Q1 2021.
182 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2021.

Based on Bailard's 13F filing for Q2 2021, filed 13 Aug 2021.